Inventiva S.A. (IVA)
IVA Stock Price Chart
Explore Inventiva S.A. interactive price chart. Choose custom timeframes to analyze IVA price movements and trends.
IVA Company Profile
Discover essential business fundamentals and corporate details for Inventiva S.A. (IVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jul 2020
Employees
114.00
Website
https://www.inventivapharma.comCEO
Frederic Cren
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Financial Timeline
Browse a chronological timeline of Inventiva S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 24 Mar 2026
Upcoming earnings on 25 Sept 2025
EPS estimate is -$0.41.
Earnings released on 23 May 2025
EPS came in at -$2.69 falling short of the estimated -$0.47 by -472.95%, while revenue for the quarter reached $6.69M , beating expectations by +4.61%.
Earnings released on 25 Sept 2024
EPS came in at -$1.01 falling short of the estimated -$0.56 by -81.10%, while revenue for the quarter reached $2.94M .
Earnings released on 27 Mar 2024
EPS came in at -$1.25 falling short of the estimated -$0.40 by -211.66%, while revenue for the quarter reached $18.19M , beating expectations by +18.93%.
Earnings released on 28 Sept 2023
EPS came in at -$1.43 falling short of the estimated -$1.27 by -13.09%, while revenue for the quarter reached $7.22M , beating expectations by +419.32%.
Earnings released on 29 Mar 2023
EPS came in at -$0.64 falling short of the estimated -$0.57 by -11.90%, while revenue for the quarter reached $16.61M , beating expectations by +5.80%.
Earnings released on 19 Sept 2022
EPS came in at -$0.75 surpassing the estimated -$0.90 by +16.59%, while revenue for the quarter reached $70.08K , missing expectations by -94.44%.
Earnings released on 3 Mar 2022
EPS came in at -$0.76 surpassing the estimated -$0.90 by +15.33%, while revenue for the quarter reached $4.60M , beating expectations by +31.17%.
Earnings released on 20 Sept 2021
EPS came in at -$0.46 surpassing the estimated -$0.91 by +48.96%, while revenue for the quarter reached $77.12K , missing expectations by -35.11%.
Earnings released on 31 Dec 2020
EPS came in at -$0.57 surpassing the estimated -$0.82 by +29.96%, while revenue for the quarter reached $258.76K , missing expectations by -94.80%.
Earnings released on 16 Sept 2020
EPS came in at -$0.32 surpassing the estimated -$0.69 by +53.20%, while revenue for the quarter reached $83.27K , missing expectations by -97.98%.
IVA Stock Performance
Access detailed IVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.